Morgan Stanley analyst Sean Laaman downgraded Halozyme Therapeutics (NASDAQ: HALO) from Overweight to Equalweight with a price target of $62.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE